| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.32 | 0.05 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.05 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.05 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.064 | 0.05 |